The risk of severe illness and hospitalization associated with COVID-19 is reportedly higher in infants who are 6 months of age or younger;1,2 however, no vaccines are currently authorized for use in children younger than 5 years of age. During the peak circulation period of the SARS-CoV-2 B.1.1.259 (omicron) variant, six-fold higher rates of COVID-19-related hospitalization among infants under 6 months of age were observed, when compared with the B.1.617.2 (delta) variant peak, and COVID-19 was reported to be the primary cause of hospitalization for 85% of the affected infants.3
Given the enhanced risk of severe COVID-19 during pregnancy, recent ‘Centers for Disease Control and Prevention’ (CDC) guidelines recommend that women who are pregnant, breastfeeding, trying to conceive or planning to conceive in the future seek vaccination against SARS-CoV-2 infection.4 Stemming from prior evidence on transplacental transfer of maternal vaccine-derived antibodies (as seen with vaccine-preventable diseases such as pertussis and seasonal influenza), maternal immunization against SARS-CoV-2 infection may provide dual benefits: it may prevent severe COVID-19 during pregnancy, and provide passive protection to infants, especially during the high-risk first 6 months of life.3,5,6
Research data have demonstrated the association between COVID-19 vaccination during pregnancy and maternally derived anti-SARS-CoV-2 antibodies detected in cord blood, breast milk and infant sera.3,5 With regard to the optimal timing of vaccination for most efficient maternal to neonatal transfer of SARS-CoV-2-specific antibodies, vaccination that occurred late in the second trimester or early in the third trimester correlated with highest antibody titers in infants.6 Furthermore, it was found that antibody levels were higher, and persisted to 6 months’ duration, in infants born to mothers who were vaccinated against COVID-19 during pregnancy, compared with infants born to mothers who had antibodies induced by natural SARS-CoV-2 infection during pregnancy.3
Halasa NB and colleagues previously reported a 61% reduced risk of COVID-19-associated hospitalization among infants aged less than 6 months old, following maternal vaccination with two doses of an mRNA vaccine during pregnancy.5 In a recent real-world multicenter network study, these investigators assessed the associations between – (i) maternal vaccination and COVID-19-related hospitalization of infants during the circulating periods of the delta and omicron variants; (ii) gestational timing of vaccination and hospitalization for COVID-19 among the studied infants; and (iii) maternal vaccination and critical COVID-19 (i.e., COVID-19 leading to ICU admission/life-supporting interventions such as non-invasive/invasive mechanical ventilation, extracorporeal membrane oxygenation and vasoactive infusions).3 Vaccine effectiveness (VE) was estimated by comparing the odds of maternal vaccination (two-dose series of BNT162b2/mRNA-1273 COVID-19 vaccine) during pregnancy between symptomatic infants aged under 6 months of age who were hospitalized for COVID-19 (case infants) versus those hospitalized without COVID-19 (control infants). The study (N=1049) included 537 ‘case’ infants (181 and 356 admissions during the delta- and omicron-predominant periods respectively) and 512 ‘control’ infants [median age: 2 months], admitted to 30 pediatric hospitals across 22 states in the U.S between July 1, 2021 and March 8, 2022.3 Infants excluded from the study were those who were subjected to delayed SARS-CoV-2 testing, those who were COVID-19 positive but hospitalized for reasons unrelated to COVID-19, born to mothers who were vaccinated less than 14 days before delivery, or born to mothers who received their third mRNA vaccine/non-mRNA vaccine during pregnancy.3
Key findings of the study are summarized below: 3
The study found that maternal vaccination with mRNA COVID-19 vaccines notably reduced the risk of COVID-19-associated hospitalization and critical illness among infants; particularly during the circulating period of the omicron variant.3
References